Robert Lowsky

Publications

• Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Arai S, Sahaf B, Narasimhan B, Chen GL, Jones CD, Lowsky R, Shizuru JA, Johnston LJ, Laport GG, Weng WK, Benjamin JE, Schaenman J, Brown J, Ramirez J, Zehnder JL, Negrin RS, Miklos DB. Blood. 2012; 119 (25): 6145-54
• Rare cells predict GVHD. Strober S, Lowsky R. Blood. 2012; 119 (21): 4820-1
• Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. Johnston L, Florek M, Armstrong R, McCune JS, Arai S, Brown J, Laport G, Lowsky R, Miklos D, Shizuru J, Sheehan K, Lavori P, Negrin R. Bone Marrow Transplant. 2012; 47 (4): 581-8
• Tolerance and withdrawal of immunosuppressive drugs in patients given kidney and hematopoietic cell transplants. Scandling JD, Busque S, Dejbakhsh-Jones S, Benike C, Sarwal M, Millan MT, Shizuru JA, Lowsky R, Engleman EG, Strober S. Am J Transplant. 2012; 12 (5): 1133-45
• Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Laport GG, Sheehan K, Baker J, Armstrong R, Wong RM, Lowsky R, Johnston LJ, Shizuru JA, Miklos D, Arai S, Benjamin JE, Weng WK, Negrin RS. Biol Blood Marrow Transplant. 2011; 17 (11): 1679-87
• Donor immunization with WT1 peptide augments antileukemic activity after MHC-matched bone marrow transplantation. Kohrt HE, Müller A, Baker J, Goldstein MJ, Newell E, Dutt S, Czerwinski D, Lowsky R, Strober S. Blood. 2011; 118 (19): 5319-29
• Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY. Naik S, Wong R, Arai S, Brown J, Laport G, Lowsky R, Miklos D, Shizuru J, Blume K, Negrin R, Johnston L. Bone Marrow Transplant. 2011; 46 (2): 192-9
• Translational studies in hematopoietic cell transplantation: treatment of hematologic malignancies as a stepping stone to tolerance induction. Strober S, Spitzer TR, Lowsky R, Sykes M. Semin Immunol. 2011; 23 (4): 273-81
• Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular remission in high-risk chronic lymphocytic leukaemia. Jones CD, Arai S, Lowsky R, Tyan DB, Zehnder JL, Miklos DB. Br J Haematol. 2010; 150 (5): 637-9
• Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged autografts after induction failure. Benjamin JE, Chen GL, Cao TM, Cao PD, Wong RM, Sheehan K, Shizuru JA, Johnston LJ, Negrin RS, Lowsky R, Laport GG. Bone Marrow Transplant. 2010; 45 (2): 303-9
• NKT cells, Treg, and their interactions in bone marrow transplantation. Kohrt HE, Pillai AB, Lowsky R, Strober S. Eur J Immunol. 2010; 40 (7): 1862-9
• Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma. Arai S, Letsinger R, Wong RM, Johnston LJ, Laport GG, Lowsky R, Miklos DB, Shizuru JA, Weng WK, Lavori PW, Blume KG, Negrin RS, Horning SJ. Biol Blood Marrow Transplant. 2010; 16 (8): 1145-54
• Nonmyeloablative conditioning with total lymphoid irradiation and antithymocyte globulin: an update. Kohrt H, Lowsky R. Curr Opin Hematol. 2009; 16 (6): 460-5
• TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Kohrt HE, Turnbull BB, Heydari K, Shizuru JA, Laport GG, Miklos DB, Johnston LJ, Arai S, Weng WK, Hoppe RT, Lavori PW, Blume KG, Negrin RS, Strober S, Lowsky R. Blood. 2009; 114 (5): 1099-109
• Total lymphoid irradiation for graft-versus-host disease protection. Kohrt H, Lowsky R. Curr Opin Oncol. 2009: 21 Suppl 1 S23-6
• Tolerance and chimerism after renal and hematopoietic-cell transplantation. Scandling JD, Busque S, Dejbakhsh-Jones S, Benike C, Millan MT, Shizuru JA, Hoppe RT, Lowsky R, Engleman EG, Strober S. N Engl J Med. 2008; 358 (4): 362-8
• High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma. Law LY, Horning SJ, Wong RM, Johnston LJ, Laport GG, Lowsky R, Shizuru JA, Blume KG, Negrin RS, Stockerl-Goldstein KE. Biol Blood Marrow Transplant. 2006; 12 (7): 703-11
• A technique of bone marrow collection from vertebral bodies of cynomolgus macaques for transplant studies. Flores MG, Holm B, Larson MJ, Lau MK, Si MS, Lowsky R, Rousvoal G, Grumet FC, Strober S, Hoppe R, Reitz BA, Borie DC. J Surg Res. 2005; 124 (2): 280-8
• CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies. Cao TM, Wong RM, Sheehan K, Laport GG, Stockerl-Goldstein KE, Johnston LJ, Shizuru JA, Negrin RS, Lowsky R. Exp Hematol. 2005; 33 (3): 279-85
• Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose. Cao TM, Shizuru JA, Wong RM, Sheehan K, Laport GG, Stockerl-Goldstein KE, Johnston LJ, Stuart MJ, Grumet FC, Negrin RS, Lowsky R. Blood. 2005; 105 (6): 2300-6
• Protective conditioning for acute graft-versus-host disease. Lowsky R, Takahashi T, Liu YP, Dejbakhsh-Jones S, Grumet FC, Shizuru JA, Laport GG, Stockerl-Goldstein KE, Johnston LJ, Hoppe RT, Bloch DA, Blume KG, Negrin RS, Strober S. N Engl J Med. 2005; 353 (13): 1321-31
• Approaches to transplantation tolerance in humans. Strober S, Lowsky RJ, Shizuru JA, Scandling JD, Millan MT. Transplantation. 2004; 77 (6): 932-6
• Short tandem repeat analysis to monitor chimerism in macaca fascicularis. Lau M, Vayntrub T, Grumet FC, Lowsky R, Strober S, Hoppe R, Larson M, Holm B, Reitz B, Borie D. Am J Transplant. 2004; 4 (9): 1543-8